More than 90 Million Cervical Cancer Cases Reported Globally

1
Global Cervical Cancer Screening Market, Patients Forecast
Category Life Science
2
Global Cervical Cancer Screening Market, Patients
Forecast Free 10 Customization in this
Report Analyst View Cervical cancer cases is
rising globally, Asia and North America both have
reported more than 90 Million cervical cancer
cases for the year 2016. Report Title
Globally Asia and North America both have
reported more than 90 Million Cervical Cancer
cases in 2016 For More Information http//www.re
nub.com/globally-asia-and-north-america-both-have-
reported-more-than-90-million-cervical-cancer-case
s-in-2016-27-nd.php

3
Globally Asia and North America both have
reported more than 90 Million Cervical Cancer
cases in 2016
Download full Report http//www.renub.com/global-
cervical-cancer-screening-market-and-patients-by-t
est-type-pap-smear-hpv-dna-via-forecast-1009-p.php

Renub Research has announced its recent
publication on Global Cervical Cancer Screening
Market Patients, By Test Type (Pap Smear, HPV
DNA, VIA) Forecast. The report gives a
comprehensive picture of Global Cervical Cancer
Screening Market with available diagnostic test
pursued by developed, developing and
under-privilege countries. In addition volume of
patients diagnosed with cervical cancer and their
mortality rate is also mentioned in this
report. Cervical cancer is malignant tumour of
the cervix and affecting women all over the
world. Cervical cancer is a disease that impacted
patients after long period, early diagnosed and
treatment of precancerous lesions is considered
to be more effective in women who sequentially
take part in screening programs. Pap smear test
is used at large-scale screening technique in
European countries however, HPV test is steadily
gaining accommodation.

4
Globally Asia and North America both have
reported more than 90 Million Cervical Cancer
cases in 2016
Significant measures taken by government and
public awareness initiatives have reinforced HPV
testing and immunization. Moreover, growing
acceptance of the HPV test especially in the
untapped developing markets will deliver
substantial growth performance. In low-income
countries, VIA (Visual inspection with acetic
acid) is used as a screening for cervical cancer
due to lower health infrastructure and fund PAP
smear and HPV test is not viable in these
countries. Over the next decades, new and
effective screening (VIA test) and early
treatment technique will be the elementary
drivers of reduced death from cervical cancer.
Many international NGOs have been establishing
pilot programme and make technical details
available to respective governments.

5
Globally Asia and North America both have
reported more than 90 Million Cervical Cancer
cases in 2016
ASCO Published Worldwide Guidance for HPV
Vaccination for Cervical Cancer Prevention The
American Society of Clinical Oncology (ASCO) has
recently published recommendation and guidelines
for human papillomavirus (HPV) vaccination for
how to prevent cervical cancer. The guideline
recommends 4 level resource setting Basic,
Limited, Enhanced and Maximal. The level includes
countries financial resources and development of
health system, infrastructure, health personnel
and accessibility of services. In geographic
areas along with limited or basic resource
settings, foremost focus on vaccinating girls
aged 9 to 14. All girl aged 15 years and older,
recommended maximal and enhanced resource
settings. If girl has received her first dose
before age 15, then she may complete two-dose
series and if not then she should take three
doses.

6
Globally Asia and North America both have
reported more than 90 Million Cervical Cancer
cases in 2016
Life Science News http//www.renub.com/life-scien
ce-1-n.php

•  Renub Research - North America
• Rajat Gupta
• 225 Kristie Ln, Roswell
• Georgia 30076, United States
• Tel [phone]
• Email info_at_renub.com
• www.renub.com
•  
• Renub Research - Asia
• Ankit Mishra
• C 86, Sector 10
• Noida 201301, India
• Tel [phone]